IDRA also was Piper-Jaffray's "stock of the year" for 2015. They should have mentioned that they must have meant "stock of the year for short sellers" because it declined steadily to finish 2015 at less than half the share price then when P-J touted them. So even big firms touting the stock didn't help them because they haven't delivered on clinical trials.

When you see something like that happen, the cynical among us (meaning me) just have to wonder if some big client had a lot of stock they wanted to unload on small investors.